This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- VEGFR2-169
- DrugBank Accession Number
- DB16152
- Background
VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for VEGFR2-169 (DB16152)
- Weight
- Average: 1073.224
Monoisotopic: 1072.577776571 - Chemical Formula
- C47H76N16O13
- Synonyms
- Elpamotide
- Vegfr2-169 peptide vaccine
- External IDs
- VEGFR2-169
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Cancer Vaccines
- Enzymes
- Enzymes and Coenzymes
- Intracellular Signaling Peptides and Proteins
- Membrane Proteins
- Peptides
- Phosphotransferases
- Phosphotransferases (Alcohol Group Acceptor)
- Protein Kinases
- Protein-Tyrosine Kinases
- Proteins
- Receptor Protein-Tyrosine Kinases
- Receptors, Growth Factor
- Receptors, Peptide
- Receptors, Vascular Endothelial Growth Factor
- Transferases
- Vaccines, Subunit
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S68632MB2G
- CAS number
- 673478-49-4
- InChI Key
- ZAJHBCDPAUKEPU-GIKXZWSFSA-N
- InChI
- InChI=1S/C47H76N16O13/c1-5-25(4)37(45(75)76)62-40(70)28(15-10-18-55-47(52)53)58-41(71)30(21-33(49)64)57-34(65)23-56-39(69)31(22-35(66)67)60-43(73)32-16-11-19-63(32)44(74)36(24(2)3)61-42(72)29(20-26-12-7-6-8-13-26)59-38(68)27(48)14-9-17-54-46(50)51/h6-8,12-13,24-25,27-32,36-37H,5,9-11,14-23,48H2,1-4H3,(H2,49,64)(H,56,69)(H,57,65)(H,58,71)(H,59,68)(H,60,73)(H,61,72)(H,62,70)(H,66,67)(H,75,76)(H4,50,51,54)(H4,52,53,55)/t25-,27-,28-,29-,30-,31-,32-,36-,37-/m0/s1
- IUPAC Name
- (2S,3S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-carboxypropanamido]acetamido}-3-carbamoylpropanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid
- SMILES
- CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 30790862
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Pancreatic Cancer 1 1 Unknown Status Treatment Pancreatic Cancer 1 1, 2 Completed Treatment Pancreatic Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0277 mg/mL ALOGPS logP -1.9 ALOGPS logP -8.5 Chemaxon logS -4.6 ALOGPS pKa (Strongest Acidic) 3.25 Chemaxon pKa (Strongest Basic) 12.47 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 20 Chemaxon Hydrogen Donor Count 17 Chemaxon Polar Surface Area 491.52 Å2 Chemaxon Rotatable Bond Count 33 Chemaxon Refractivity 290.03 m3·mol-1 Chemaxon Polarizability 108.81 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:14 / Updated at December 20, 2020 03:38